Teva Pharmaceutical Industries Limited (TEVA) Q2 2026 Earnings Call

Investor webinar replay

Replay transcript excerpt

Hello, everybody, and welcome to the Q2 2026 Teva Pharmaceutical Industries earnings conference call. My name is Elliot. I'll be coordinating your call today. If you would like to ask a question during today's event, please press star followed by 1 on your telephone keypad. And I'll hand over to Christopher Stevo. Please go ahead. Thank you, Elliot. Good morning and good afternoon, everyone. Thank you for joining us on our second quarter call. Obviously, our materials are posted to our website this morning, so please see those. And before I turn the call over to our CEO, Richard Francis, I'd like to remind everyone that we'll be making forward-looking statements on this call. The company cautions investors that any forward-looking statement involves risks and uncertainties and is not a guarantee of future performance. Actual results may differ materially from those expressed or implied in the forward-looking statements due to a variety of factors. These factors are described in our earnings press release in our most recent forms 10Q and 10K filed with the SEC. Any statements that we make are only as of today, and we undertake no obligation to update these statements subsequently. With that, Richard Francis. Thanks, Chris, and good morning and good afternoon, everybody. Thank you for joining the call today. And on me, joining me, the call today will be Dr. Eric Hughes, Head of Global R&D and Chief Medical Officer, and Eli Khalif, our Chief Financial Officer. Now, moving on to the slide I always start with. the Pivot to Growth strategy that we launched in 2023 that's based on these four pillars. We'll summarize how we've performed against these four pillars in quarter two, but just to give you a quick overview. On delivering our growth engines, Esteto, Jovi and Yosetti...